Impact of SGLT2i on bone health in patients with lupus nephritis: randomized double blinded placebo-controlled clinical trial
Dapagliflozin did not significantly affect bone and mineral metabolism in patients with lupus nephritis over a 12-month period. These findings suggest that dapagliflozin is unlikely to have adverse effects on bone health in patients with lupus nephritis, though further research is warranted to confirm these results over longer periods in a larger cohort.
Authors
- Kareem A. Nabieh
- Eman Nagy (ORCID: https://orcid.org/0000-0003-3062-2313)
- Amr El‐Husseini (ORCID: https://orcid.org/0000-0001-9072-5029)
- Mohamed Sobh (ORCID: https://orcid.org/0000-0002-6065-5725)
- Wael I. Mortada (ORCID: https://orcid.org/0000-0001-7797-0302)
- Mohamed Abou El‐Ghar (ORCID: https://orcid.org/0000-0003-2713-4394)
- Nourelsabah Mohamed (ORCID: https://orcid.org/0009-0005-8807-8527)
- Ehab W. Wafa
- M. Badawi
Institutions
- Mansoura University (EG)
Publication Details
- Journal
- Journal of Nephrology
- Published
- 2025-07-13
- DOI
- https://doi.org/10.1007/s40620-025-02351-0
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00